rimegepant: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
rimegepant: clinical details
Prescribing considerations
- Confirm the migraine indication and whether treatment is intended for an acute attack or prevention.
- Review all medicines and herbal products for CYP3A4 and P-glycoprotein interactions.
- Experience in people aged 65 years or older is limited.
- Safety and efficacy have not been established below 18 years.
- Consider medication-overuse headache if headaches become frequent or daily during regular use of acute treatments.
Contraindications and cautions
- Hypersensitivity to rimegepant or any excipient.
- Avoid in severe hepatic impairment and end-stage renal disease, including dialysis.
- Concomitant strong CYP3A4 inhibitors and strong or moderate CYP3A4 inducers are not recommended.
Monitoring
- No routine laboratory-monitoring schedule is specified in the product information.
- Assess migraine frequency, clinical response and adverse effects.
- Check for new interacting medicines and symptoms of immediate or delayed hypersensitivity.
- Use caution with frequent use in severe renal impairment.
Clinical pharmacology
Rimegepant is a selective, high-affinity CGRP receptor antagonist. It is mainly metabolised by CYP3A4, with a smaller CYP2C9 contribution, and is a substrate of P-glycoprotein and BCRP. Its approximate elimination half-life in healthy adults is 11 hours.
Formulation and product differences
- The selected product is an oral lyophilisate designed to dissolve on or under the tongue without liquid.
- It contains gelatin, mannitol, mint flavour and sucralose and should remain in its moisture-protective blister until use.
rimegepant interactions
Check prescribed, over-the-counter and herbal products with a pharmacist or prescriber because some medicines substantially alter rimegepant exposure.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole and ritonavir
Can markedly increase rimegepant exposure; combined use is not recommended.
Moderate CYP3A4 inhibitors, including diltiazem, erythromycin and fluconazole
Can increase rimegepant exposure, so use and timing need review.
Strong or moderate CYP3A4 inducers, including rifampicin, phenobarbital, efavirenz, modafinil and St John's wort
Can substantially reduce rimegepant exposure and effectiveness; combined use is not recommended.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.